Baidu
map

精神心理科

订阅

MedSci主页 / 所有栏目 / 精神心理科

治疗精神分裂症：SEP-363856已获FDA突破性疗法认定

2019-05-12 不详 网络

精神分裂症SEP-363856FDA
关注

Sunovion和PsychoGenics公司近日宣布，美国食品和药品监督管理局（FDA）已经授予SEP-363856突破性疗法认定以治疗精神分裂症。突

Sunovion和PsychoGenics公司近日宣布，美国食品和药品监督管理局（FDA）已经授予SEP-363856突破性疗法认定以治疗精神分裂症。突破性疗法认定旨在加快针对严重或危及生命的疾病的药物开发和审查，入选药物需要在一个或多个重要临床终点上显示出相对于现有疗法的实质性改善。

Sunovion的首席执行官Antony Loebel表示：“精神分裂症大约影响美国240万人，已成为主要的公共卫生挑战。患者的思维、认知和行为的持续异常已严重损害了生活质量。自20世纪50年代抗精神病药物疗法出现以来，精神分裂症的治疗方面几乎没有取得重大进展。本次突破性疗法认定强调了SEP-363856作为精神分裂症患者的新疗法的潜力”。


原始出处：

http://www.firstwordpharma.com/node/1640320?tsid=4#axzz5ngGcHmd9

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=366342, encodeId=829f366342b3, content=向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri May 17 10:05:17 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366259, encodeId=4c58366259d2, content=这是天大的好消息，希望能及时追踪报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cfb2413372, createdName=1237efc1m07暂无昵称, createdTime=Wed May 15 17:53:52 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250885, encodeId=ecbb125088502, content=<a href='/topic/show?id=bcaf1613940' target=_blank style='color:#2F92EE;'>#SEP-363856#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16139, encryptionId=bcaf1613940, topicName=SEP-363856)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404113, encodeId=82f51404113ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536183, encodeId=4d691536183da, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-17 坚强007

    向挑战病魔的科研人员致敬！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=366342, encodeId=829f366342b3, content=向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri May 17 10:05:17 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366259, encodeId=4c58366259d2, content=这是天大的好消息，希望能及时追踪报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cfb2413372, createdName=1237efc1m07暂无昵称, createdTime=Wed May 15 17:53:52 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250885, encodeId=ecbb125088502, content=<a href='/topic/show?id=bcaf1613940' target=_blank style='color:#2F92EE;'>#SEP-363856#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16139, encryptionId=bcaf1613940, topicName=SEP-363856)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404113, encodeId=82f51404113ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536183, encodeId=4d691536183da, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-15 1237efc1m07暂无昵称

    这是天大的好消息，希望能及时追踪报道

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=366342, encodeId=829f366342b3, content=向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri May 17 10:05:17 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366259, encodeId=4c58366259d2, content=这是天大的好消息，希望能及时追踪报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cfb2413372, createdName=1237efc1m07暂无昵称, createdTime=Wed May 15 17:53:52 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250885, encodeId=ecbb125088502, content=<a href='/topic/show?id=bcaf1613940' target=_blank style='color:#2F92EE;'>#SEP-363856#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16139, encryptionId=bcaf1613940, topicName=SEP-363856)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404113, encodeId=82f51404113ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536183, encodeId=4d691536183da, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-14 bshuang

    #SEP-363856#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=366342, encodeId=829f366342b3, content=向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri May 17 10:05:17 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366259, encodeId=4c58366259d2, content=这是天大的好消息，希望能及时追踪报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cfb2413372, createdName=1237efc1m07暂无昵称, createdTime=Wed May 15 17:53:52 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250885, encodeId=ecbb125088502, content=<a href='/topic/show?id=bcaf1613940' target=_blank style='color:#2F92EE;'>#SEP-363856#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16139, encryptionId=bcaf1613940, topicName=SEP-363856)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404113, encodeId=82f51404113ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536183, encodeId=4d691536183da, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-14 heli0118

    #精神分裂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=366342, encodeId=829f366342b3, content=向挑战病魔的科研人员致敬！, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Fri May 17 10:05:17 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366259, encodeId=4c58366259d2, content=这是天大的好消息，希望能及时追踪报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cfb2413372, createdName=1237efc1m07暂无昵称, createdTime=Wed May 15 17:53:52 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250885, encodeId=ecbb125088502, content=<a href='/topic/show?id=bcaf1613940' target=_blank style='color:#2F92EE;'>#SEP-363856#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16139, encryptionId=bcaf1613940, topicName=SEP-363856)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404113, encodeId=82f51404113ea, content=<a href='/topic/show?id=7366e6493be' target=_blank style='color:#2F92EE;'>#精神分裂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76493, encryptionId=7366e6493be, topicName=精神分裂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536183, encodeId=4d691536183da, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Tue May 14 04:07:00 CST 2019, time=2019-05-14, status=1, ipAttribution=)]
    2019-05-14 zhwj

    #突破性疗法#

    0

相关资讯

Science+Sci Transl Med：中南大学在Science及其子刊揭示精神疾病发病机理

近日，国际顶级学术期刊Science和Science Translational Medicine同期发表了中南大学生命科学学院、医学遗传学研究中心刘春宇教授和陈超副教授团队的3项重要研究成果。这些研究发现加深了我们对精神分裂症、双向情感障碍和自闭症发病机制的理解，为今后的致病机制的深入研究、寻找疾病的药物治疗靶点提供重要基础。

JAMA Psychiatry：14余万SMI患者的观察性研究提示他汀或有抗精神病效果

1月9日，在线发表于《JAMA Psychiatry》杂志上的一项研究显示，他汀、L型钙拮抗剂（如维拉帕米）和双胍类药物（二甲双胍），这些用来治疗心血管病和糖尿病的药物，对双相情感障碍（BPD）、精神分裂症或非情感性精神病等严重精神疾病（SMI）的患者也有一定疗效。

Brain Behav Immun：弓形虫可能会增加精神分裂症风险

铲屎官及时“铲屎”很重要！

JAMA Psychiatry：发现 青少年大脑结构异常与精神疾病风险显著相关

青春期的大脑发育异常是否会埋下成年后罹患精神分裂症的“种子”，如何发现这颗隐匿的种子？ 近日，复旦大学类脑智能科学与技术研究院冯建峰课题组对来自英美等6个国家20余所研究机构的超过1万例影像遗传学数据进行计算分析，通过全脑全基因组范围的“广泛搜索”，研究发现与青春期大脑壳核体积最为相关的基因位点同时也是精神分裂症的风险位点。

首发精神分裂症的治疗：联用西酞普兰

首发精神分裂症（first-episode schizophrenia，FES）患者经常会表现出阴性症状、亚综合症抑郁和功能障碍，以往有证据表明抗抑郁药可以减轻慢性精神分裂症患者的阴性症状，但并不推荐用于不伴有抑郁的 FES 患者的维持治疗。由于此前并没有研究调查抗抑郁药对于 FES 患者的精神病理学相关作用，纽约 Nathan Kline 精神病研究所的 Goff 等研究者大胆假设：西酞普兰对

Schizophrenia Research：发现精神分裂症患者期待愉快情绪损伤

关于精神分裂症患者快感缺失的研究发现一直以来都存在着争论，有些研究利用自我报告问卷或者临床访谈评估发现精神分裂症患者存在特质性快感缺失，但另一些研究利用实验室情绪体验任务却并没有发现他们表现出状态性快感缺失问题。然而，人们并不清楚出现这种分离现象的心理病理机制是什么。

Baidu
map
Baidu
map
Baidu
map